The 7 most recent market catalysts affecting $ALZN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 55
Alzamend Neuro Regains Nasdaq Compliance
Alzamend Neuro announced it has received a notification from Nasdaq confirming compliance with Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 millio…
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 92
Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY
Alzamend Neuro's Q1 earnings report reveals a substantial miss on EPS expectations and a complete absence of sales, mirroring the previous year. This is a critical negative catalys…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 65
Alzamend Neuro Files Prospectus Related To The Resale Of Up To 98.4M Common Shares By Selling Stockholder
Alzamend Neuro filed an 8-K to announce a prospectus for the resale of up to 98.4 million common shares by a selling stockholder. This is a significant number of shares relative to…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 55
Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026
Alzamend Neuro, a clinical-stage biopharmaceutical company, announced the acceptance of an abstract for presentation at Neuroscience 2026. The abstract concerns resting-state fMRI …
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 55
Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26
Ascendiant Capital analyst Edward Woo maintained a 'Buy' rating on Alzamend Neuro (ALZN) and raised the price target from $25 to $26. This action signals continued analyst confiden…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 55
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop
Alzamend Neuro (ALZN) announced that its Phase 1/2A lithium imaging data for AL001 has been accepted for an oral presentation at the ISMRM Workshop in September 2026. This is a pos…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 75
Alzamend Neuro Signs $25M Securities Purchase Agreement With Ault Lending; Alzamend Receives $7.5M In Gross Proceeds Form Initial Tranche
Alzamend Neuro, a clinical-stage biopharmaceutical company, announced a Securities Purchase Agreement with Ault Lending for up to $25 million, with an initial tranche of $7.5 milli…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.